INVVAX

We at InvVax are looking elsewhere, however. We believe there is a weakness in these viruses that can be exploited by a vaccine to prevent infection and disease. The weakness is this: these viruses, as with virtually all pathogens, have stretches within their proteins that are fixed, that is, any mutations here will result in a virus unable to replicate - in essence, a dead virus. By definition, these are the most invariant stretches. Present vaccine technology allows one to pick and choose which stretches to target, although this technology is still in its infancy. By selecting a few of these invariant stretches, one would "back" the virus into a "corner" from which it cannot escape... These invariant regions and the screening methodology used to identify them are patent-pending. We have filed a patent for these 15 invariant epitopes. In addition, we are developing a much broader patent strategy with Wilson Sonsini.

Primary location: Pasadena United States